摘要
目的评估英夫利昔治疗溃疡性结肠炎临床疗效。方法选取我院2013年1月-2014年10月期间收治的溃疡性结肠炎的患者68例进行研究,按照不同的治疗方法分为对照组（n=33）和观察组（n=35）,对照组予以美沙拉嗪治疗,观察组予以英夫利昔治疗,比较两组患者的治疗效果。结果对照组的总有效率为69%,观察组的总有效率为91%,观察组的总有效率高于对照组,差异有统计学意义,P〈0.05,对照组患者不良反应的发生率为6%,观察组患者不良反应的发生率为3%,两组患者的不良反应发生率比较,差异无统计学意义,P〉0.05。结论英夫利昔治疗溃疡性结肠炎安全、有效、不良反应少,在临床上有重要的应用价值。
Objective Evaluation on clinical efficacy ofinfliximab in the treatment of ulcerative colitis. Methods 68 patients with ulcerative colitis admitted to our hospital from January 2013 to October 2014 were selected to study, according to the different treatment methods, they were divided into control group （ n=33 ） and the observation group （ n=35 ）, the control group received mesalazine treatment, the observation group received infliximab treatment, then compare the effect between the two groups. Results The total efetive rate of the control group was 69%, the total effective of the observation group was 91%, the total efficiency of observation group was higher than the control group, the difference was statistically significant, P〈0.05, the rate of adverse reactions in control group was 6%, the occurrence of adverse reactions in observation group was 3%, comparing the incidence of adverse reactions of the two groups, the difference was not statistically significant, P〉0.05, Conclusion Infliximab treatment of ulcerative colitis is safe, effective, and less adverse reactions in clinical important value.
出处
《中国卫生标准管理》
2015年第12期61-62,共2页
China Health Standard Management
